A Phase 3 interventional study of Recombinant Human-Luteinizing Hormone (Luveris) in Infertility and Ovarian Stimulation, sponsored by EMD Serono. Completed. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing lutropin alfa in Infertility — 1 open to participants now, 1 under way, 1 of them phase 3. lutropin alfa · Infertility.
Among the 11 studies testing lutropin alfa in Infertility, this one is the 10th largest by enrollment, is the only one that started in 2004, is one of 3 in phase 3, and was the 5th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 11 studies testing lutropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
By country, each count listing its studies:
lutropin alfa: first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2004.
This study's enrollment of 55 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 90 across the 11 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 24th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2004, is one of 11 in phase 3, and was the 24th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
1 of the studies testing lutropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing lutropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
In-vitro fertilization (IVF) of human oocytes followed by the replacement of embryo in the uterine cavity has become a well established treatment for female infertility attributable to damaged fallopian tubes, endometriosis or unexplained causes where alternative forms of therapy have failed. The most commonly used protocols of follicular stimulation now employs follicle stimulating hormone (FSH) and long-acting agonists of gonadotropin releasing hormone (GnRH) to prevent the occurrence of a mid-cycle luteinizing hormone (LH) surge and to ensure the induction of well-synchronized larger cohort of ovarian follicles.
The results of a number of studies have demonstrated that in the majority of clinical situations, FSH administration alone is sufficient to achieve successful follicular development. A study had shown that in subjects receiving recombinant human-follicle stimulating hormone (r-hFSH) and recombinant human-luteinizing hormone (r-hLH), pregnancy rates were similar in the younger and older age groups, however, in women receiving r-hFSH alone, there was a significant decline in pregnancy rates for women 35 and older. This particular study also went on to show that the subgroup of women 35 and older, may benefit from supplementary r-hLH. A number of studies have been conducted to assess the safety and efficacy of r-hLH administered concomitantly with r-hFSH in the presence of developing follicles to reduce the rate of growth of intermediate and small follicles while allowing the dominant follicle to continue to progress.
This was a Phase III, open-label, multicentre study to evaluate safety and efficacy of addition of Recombinant Human-Luteinizing Hormone (Luveris) to a standard assisted reproductive technologies (ART) protocol.
Luteinizing hormone is a heterodimeric glycoprotein composed of a non-covalent association of an α and a β subunit. Prior to the generation of human-LH (hLH) through recombinant technology, hLH had only been available for therapeutic use as human menopausal gonadotropins (hMG), a co-extracted, purified preparation of hLH and hFSH from urine of post menopausal women. Recombinant Human-Luteinizing Hormone (Luveris) has been found to be well tolerated in human pharmacokinetic and pharmacodynamic studies at doses of up to 40,000 IU in healthy female volunteers without any Serious Adverse Event (SAE) experience being reported.
OBJECTIVES
In this study, subjects were first treated with a GnRH agonist to induce pituitary desensitization according to centre's standard practice followed by administration of r-hFSH. All subjects were then treated with Recombinant Human -Luteinizing Hormone (Luveris)150 IU per day subcutaneous (s.c.) from Day 6 of stimulation of their ART treatment cycle, continuing at the same dose until injection of hCG upto and including day of last FSH dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who in the opinion of the treating investigator met any of the following criteria to require r-LH supplementation during the ovarian stimulation:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI)
Mean number of metaphase II oocytes was calculated for each participant undergoing ovum pick up for ICSI. ICSI is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.
Time frame: On the day of ovum pick up (Day 1 or 2 after human chorionic gonadotropin [hCG] administration).
Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF)
Mean number of oocytes undergoing ovum pick up for IVF were calculated for each participant. IVF is a process by which egg cells are fertilized by sperm outside the body, in-vitro.
Time frame: On the day of ovum pick up (Day 1 or 2 after hCG administration).
Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up
Mean number of oocytes retrieved per number of follicles aspirated on the day of ovum pick up was calculated. Oocyte retrieval is a technique used in in vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
Time frame: On day of ovum pick up (Day 1 or 2 after hCG administration)
Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies
Biochemical pregnancy: A positive pregnancy test defined as hCG level \>10 IU/L in a sample taken at least 14 days after Day 3 embryo transfer or 12 days after Day 5/6 embryo transfer with no further ultrasound confirmation of the existence of a gestational sac in the uterus. Clinical pregnancy: Existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.
Time frame: Post-hCG days 15-20 and post-hCG days 35-42.
Number of Participants With Multiple Pregnancies
Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.
Time frame: Post-hCG Day 35-42.
Number of Live Births
A live birth occurs when a fetus, whatever its gestational age, exits the maternal body and subsequently shows any sign of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord, for however brief a time and regardless of whether the umbilical cord or placenta are intact.
Time frame: Post-hCG days 15-20 to pregnancy follow up.
Pregnancy Loss Per Clinical Pregnancy
Preclinical miscarriage: Spontaneous cessation of a biochemical pregnancy. Early spontaneous abortion: Any spontaneous abortion occurring after confirmation of clinical pregnancy and before completion of 12 weeks of gestation. Late spontaneous abortion: any spontaneous abortion occurring between completion of 12 weeks of gestation and prior to a viable stage. Pregnancy loss per clinical pregnancy was measured as a percentage.
Time frame: Post-hCG days 35-42.
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation.
AEs: Any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. TEAEs: AEs that occur during treatment with the study drug. It also included incidences of mild, moderate and severe ovarian hyperstimulation syndrome (OHSS). SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.
Time frame: From stimulation Day 1 (S1) to post-hCG days 35-42 (safety visit).
Participants were recruited in 4 study centers in Canada from September 2004 to October 2005.
| Milestone | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Started | 52 |
| Completed | 46 |
| Not completed | 6 |
| Withdrew: Lack of ovarian response | 2 |
| Withdrew: No oocytes retrieved | 3 |
| Withdrew: No fertilization | 1 |
Mean number of metaphase II oocytes was calculated for each participant undergoing ovum pick up for ICSI. ICSI is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.
| Metaphase II Oocytes | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) | 9.5 ± 4.2 |
Mean number of oocytes undergoing ovum pick up for IVF were calculated for each participant. IVF is a process by which egg cells are fertilized by sperm outside the body, in-vitro.
| oocytes | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF) | 7.5 ± 6.8 |
Mean number of oocytes retrieved per number of follicles aspirated on the day of ovum pick up was calculated. Oocyte retrieval is a technique used in in vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.
| oocytes per aspirated follicle | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up | 0.9 ± 0.2 |
Biochemical pregnancy: A positive pregnancy test defined as hCG level \>10 IU/L in a sample taken at least 14 days after Day 3 embryo transfer or 12 days after Day 5/6 embryo transfer with no further ultrasound confirmation of the existence of a gestational sac in the uterus. Clinical pregnancy: Existence of at least one ultrasonography confirmed gestational sac in the uterus, with or without heartbeat.
| participants | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Participants with confirmed biochemical pregnancy | 22 |
| Participants with confirmed clinical pregnancy | 14 |
Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.
| participants | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Number of Participants With Multiple Pregnancies | 4 |
A live birth occurs when a fetus, whatever its gestational age, exits the maternal body and subsequently shows any sign of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord, for however brief a time and regardless of whether the umbilical cord or placenta are intact.
| Live births | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Number of Live Births | 13 |
Preclinical miscarriage: Spontaneous cessation of a biochemical pregnancy. Early spontaneous abortion: Any spontaneous abortion occurring after confirmation of clinical pregnancy and before completion of 12 weeks of gestation. Late spontaneous abortion: any spontaneous abortion occurring between completion of 12 weeks of gestation and prior to a viable stage. Pregnancy loss per clinical pregnancy was measured as a percentage.
| Percentage of pregnancy loss | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Pregnancy Loss Per Clinical Pregnancy | 7.14 |
AEs: Any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. TEAEs: AEs that occur during treatment with the study drug. It also included incidences of mild, moderate and severe ovarian hyperstimulation syndrome (OHSS). SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.
| Number of participants | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| TEAEs | 15 |
| SAEs | 3 |
| Discontinuation due to AEs | 0 |
Collected over AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 35-42 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recombinant Human-Luteinizing Hormone (Luveris) | — | 3/52 (5.8%) | 15/52 (28.8%) |
| Event | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Abdominal painGastrointestinal disorders | 1/52 |
| MetrorrhagiaReproductive system and breast disorders | 1/52 |
| Post procedural hemorrhageInjury, poisoning and procedural complications | 1/52 |
| Event | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Local tolerability of injectionsGeneral disorders | 5/52 |
| Ovarian Hyperstimulation SyndromeReproductive system and breast disorders | 3/52 |
| ConstipationGastrointestinal disorders | 2/52 |
| DiarrheaGastrointestinal disorders | 2/52 |
| FatigueGeneral disorders | 2/52 |
| Procedural painInjury, poisoning and procedural complications | 2/52 |
| Abdominal distensionGastrointestinal disorders | 1/52 |
| FlatulenceGastrointestinal disorders | 1/52 |
| Injection site painGeneral disorders | 1/52 |
| Vulvovaginal mycotic infectionInfections and infestations | 1/52 |
| Age Continuous(years) | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Mean | 34.6 ± 3.6 |
| Age, Customized(participants) | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| <35 years | 22 |
| >=35 years | 30 |
| Sex: Female, Male(Participants) | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Female | 52 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Asian | 3 |
| White | 47 |
| Hispanic | 1 |
| Aboriginal | 1 |
| Region of Enrollment(participants) | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| Canada | 52 |
| Smoking(participants) | Recombinant Human-Luteinizing Hormone (Luveris) |
|---|---|
| 0 cigarettes per day | 50 |
| 6-20 cigarettes per day | 1 |
| >20 cigarettes per day | 1 |
No study locations are listed for this record.
The record gives a start of Sep 2004 and a primary completion of Sep 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutropin alfa